Quantitative Analysis of Melanocytic Tissue Array Reveals Inverse Correlation between Activator Protein-2α and Protease-Activated Receptor-1 Expression during Melanoma Progression  by Tellez, Carmen S. et al.
Quantitative Analysis of Melanocytic Tissue Array
Reveals Inverse Correlation between Activator
Protein-2a and Protease-Activated Receptor-1
Expression during Melanoma Progression
Carmen S. Tellez1, Darren W. Davis2, Victor G. Prieto3, Jeffrey E. Gershenwald4, Marcella M. Johnson5,
Marya F. McCarty2 and Menashe Bar-Eli2
The identification of molecular markers of melanoma progression is needed to more accurately stage and
identify treatments for patients with malignant melanoma. Previously, we demonstrated that loss of the activator
protein-2a (AP-2a) expression results in overexpression of the protease-activated receptor-1 (PAR-1) in human
melanoma cell lines. Here, we used a tissue microarray platform that consisted of 64 melanocytic lesions,
including dysplastic nevi (N¼ 21), primary melanoma (N¼ 20), and metastatic melanoma (N¼ 23). We analyzed
the expression of AP-2 and PAR-1 simultaneously by immunofluorescent microscopy with an automated
quantification laser scanning cytometer. AP-2 was highly expressed in normal cutaneous melanocytes and
dysplastic nevi but not in melanoma metastases. We observed a significantly higher number of AP-2-positive
cells in the dysplastic nevi (P¼ 0.0013) and primary melanoma (P¼ 0.0023) compared to the metastatic
melanoma. In contrast, we observed a significantly higher percentage of PAR-1-positive cells in the metastatic
melanoma compared to dysplastic nevi (P¼ 0.0072) and primary melanoma (P¼ 0.0138). Increased expression of
PAR-1 in metastatic melanomas contributes to tumor progression by modulating expression of genes, such as
IL-8, matrix metalloproteinase-2, vascular endothelial growth factor, platelet-derived growth factor, and
integrins. These findings support our hypothesis that loss of AP-2 is a crucial event in the progression of
human melanoma and contributes to the acquisition of the metastatic phenotype via upregulation of PAR-1.
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INTRODUCTION
Activator protein-2a (AP-2a), a 52-kDa DNA-binding protein,
has been shown to control gene expression in neural crest
and epidermal cell lineages and functions as a tumor
suppressor-like gene in carcinogenesis (Imagawa et al.,
1987; Williams et al., 1988; Mitchell et al., 1991). Studies
performed in vitro revealed that transfection of AP-2 into
human hepatoblastoma and colon adenocarcinoma cell
lines, that lack endogenous AP-2 expression, resulted in a
reduction in cell division and stable colony formation (Zeng
et al., 1997a). Loss of AP-2 expression has been reported in
several cancers including breast (Turner et al., 1998; Gee
et al., 1999), colorectal (Ropponen et al., 1999), prostate
(Lipponen et al., 2000), and melanoma (Karjalainen et al.,
1998). Previously, we have demonstrated that the progression
of human cutaneous melanoma is associated with loss of
AP-2 expression during the transition from radial growth
phase to vertical growth phase (Bar-Eli, 1997). Moreover, re-
expression of AP-2 in highly metastatic human melanoma
cells suppressed their growth and metastatic potential in nude
mice (Huang et al., 1998; Jean et al., 1998). In addition,
inactivation of AP-2 in primary cutaneous melanoma cells
increased tumor growth and metastases formation in vivo
(Gershenwald et al., 2001).
The biological significance of another group of molecules
related to the physiology and pathology of human neoplasms,
the protease-activated receptors (PARs), has drawn consider-
able interest recently. PARs constitute a family of G protein-
coupled receptors that are enzymatically activated by serine
proteases through cleavage of their amino terminal domain,
and their activation is implicated in numerous biological
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effects, including inflammation (Asokananthan et al., 2002),
coagulation (Coughlin, 2001; Ruf et al., 2003), mitogenesis
(Madamanchi et al., 2001), and cell proliferation (Darmoul
et al., 2003). Overexpression of the protease-activated
receptor-1 (PAR-1) has been reported in a variety of human
carcinoma cell lines, including colon (Wojtukiewicz et al.,
1995), laryngeal (Kaufmann et al., 1997), breast (Even-Ram
et al., 1998; Henrikson et al., 1999), pancreatic (Rudroff
et al., 1998), and oral squamous cell neoplasms (Liu et al.,
2001). In cutaneous melanomas, we observed a correlation
between the expression of PAR-1 and the metastatic potential
of human melanoma cell lines (Tellez et al., 2003). Direct
evidence demonstrating a physiological role for PAR-1 in the
melanoma metastatic cascade was shown in a murine
melanoma cell line, such that PAR-1 was the rate-limiting
factor in experimental pulmonary metastasis assay (Nierodzik
et al., 1998).
In our previous investigation, we demonstrated that loss of
AP-2 expression results in overexpression of PAR-1 in human
melanoma cell lines (Tellez et al., 2003), which prompted us
in this study to evaluate the expression of AP-2 and PAR-1
in clinical specimens. This retrospective study was designed
to evaluate the level of expression of AP-2 and PAR-1 in
clinical samples of dysplastic nevi, primary melanomas, and
melanoma metastases. Our hypothesis is that loss of AP-2
expression results in overexpression of PAR-1, which
contributes to the acquisition of the metastatic phenotype.
We utilized a human melanoma tissue microarray platform to
analyze simultaneously the expression of AP-2 and PAR-1 by
immunofluorescence microscopy with an automated quanti-
fication laser scanning cytometer (LSC). We found that AP-2
was highly expressed in dysplastic nevi and primary
melanomas and that there was a significant reduction in
AP-2 expression in metastatic melanomas. Furthermore, we
found that upregulation of PAR-1 expression in malignant
melanomas significantly correlated with diminished AP-2
expression. These results are consistent with our hypothesis
and our previous findings that loss of AP-2 is a crucial event
in melanoma progression.
RESULTS
AP-2 and PAR-1 expression in melanocytic lesions
To compare the expression of AP-2 and PAR-1 in benign
epidermal melanocytes and malignant melanoma, we uti-
lized a tissue microarray of formalin-fixed paraffin-embedded
melanocytic lesions for evaluation by immunofluorescent
staining and LSC-mediated quantification. The LSC is a
microscope-based cytofluorometer, which has attributes of
both flow and image cytometry (Darzynkiewicz et al., 1999).
Expression is quantitated by laser-excited fluorescence that is
emitted from a flurochrome on individual cells, which can be
rapidly measured at multiple wavelengths with high sensi-
tivity and accuracy. The tissue microarray consisted of 64
cases of melanocytic lesions consisting of samples from cases
of dysplastic nevi (N¼ 21), primary melanoma (N¼ 20), and
metastatic melanoma (N¼23). In this study, LSC-meditated
expression analysis of AP-2 and PAR-1 was performed
simultaneously within the sample by using the melanoma
antigen recognized by T cells (MART-1) to detect melano-
cytic cells. The MART-1 gene encodes a melanoma
differentiation protein expressed in normal melanocytes and
majority of metastatic melanoma cells (Coulie et al., 1994;
Fetsch et al., 1999), thereby making it an ideal marker for
automated detection of melanocytic lesions. The expression
of MART-1, AP-2, and PAR-1 was visually inspected to verify
the quality of immunofluorescent signal (Figure 1). The
expression of MART-1, AP-2, and PAR-1 was similar within
the center and the periphery of the specimens.
To quantify AP-2 and PAR-1 expression by LSC, we
evaluated the melanocytic lesions for MART-1 expression.
There were no significant differences in the number of MART-
1-positive cells between dysplastic nevi, primary melanoma,
or metastatic melanoma (Figure 2). We therefore used MART-
1 as a melanocytic reference for the automated LSC analysis
of AP-2 and PAR-1 expression in each diagnostic group.
MART-1 AP-2
PAR-1 OVERLAY
Figure 1. Immunofluorescent detection of MART-1, AP-2, and PAR-1.
A representative LSC-generated image of a dysplastic nevus specimen
demonstrates optimization of antigen detection for MART-1 (red), AP-2
(green), and PAR-1 (blue). Original magnification  200.
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Figure 2. LSC-based detection of MART-1-positive cells. Box plot
demonstrating the percentage of MART-1-positive cells from each diagnosis
group. The percentage of MART-1-positive cells was similar between
diagnosis groups. No significant difference between diagnosis groups.
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For each case, the LSC generated coordinate position
maps as shown in Figure 3. The percentage of positive AP-2
cells in dysplastic nevi and primary melanoma specimens
was similar. There were, however, significantly more positive
AP-2 cells observed in the dysplastic nevi cases than in the
metastatic melanoma cases (P¼0.0013; Figure 4a). Expres-
sion of AP-2 significantly decreased with progression from
primary to metastatic melanoma (P¼0.0023; Figure 4a). In
contrast, there was a significant increase in PAR-1-positive
cells in metastatic melanomas than in dysplastic nevi
(P¼0.0072; Figure 4b). LSC-mediated analysis revealed a
statistically significant increase in expression of PAR-1 in
metastatic melanomas compared to primary melanomas
(P¼0.0138; Figure 4b). No significant difference in the
number of PAR-1-positive cells was observed in primary
melanoma compared to dysplastic nevi cases. Statistical
analysis of AP-2 expression in each diagnosis group is
presented in Table 1, and the analysis for PAR-1 expression
is presented in Table 2.
Inverse correlation between AP-2 and PAR-1 expression in
metastatic melanoma
The correlation between AP-2 and PAR-1 expression was
evaluated for each diagnosis group. As hypothesized, the
expression level of AP-2 decreased and PAR-1 expression
level increased in metastatic melanoma: the number of cells
expressing AP-2 was significantly negatively correlated with
PAR-1-positive cells in each diagnosis group (Table 3).
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Figure 3. Representative scattergrams from each diagnosis group. For
each case, a scattergram was generated: the x axis represents PAR-1-positive
cells and the y axis represents AP-2-positive cells. Gates were set based
on negative controls.
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Figure 4. Expression analysis of AP-2 and PAR-1. Box plots demonstrating the
median and range of (a) AP-2 expression and (b) PAR-1 expression in each
diagnosis group.
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DISCUSSION
The molecular events that are associated with melanoma
progression are not very well defined. Therefore, there is a
need to identify melanoma progression markers. This study
describes a feasible strategy for validating molecular markers
of melanoma progression. To define the possible role of AP-2
and PAR-1 in melanocytic tumor progression, we evaluated
AP-2 and PAR-1 expression levels in dysplastic and malignant
melanocytic lesions. We found that the level of AP-2
expression was inversely related to tumor progression and
the level of PAR-1 expression was directly related to tumor
progression.
The transcription factor AP-2 functions as a putative tumor
suppressor, and decreased expression of AP-2 compared
with that of a normal tissue was reported in several human
cancers including breast, prostate, colorectal, and melanoma
(Karjalainen et al., 1998; Turner et al., 1998; Gee et al., 1999;
Ropponen et al., 1999; Lipponen et al., 2000). In agreement
with previous reports, we found in a recent study that AP-2
was highly expressed in normal cutaneous melanocytes,
dysplastic nevi, and primary melanoma specimens (Berger
et al., 2005). As shown here and previous studies, these data
indicated that AP-2-positive cells significantly decrease
during melanoma progression.
In a recent study, Massi et al. (2005) demonstrated that
PAR-1 expression is altered in melanomas in comparison
with common melanocytic nevi. Our results indicate that
PAR-1 is significantly overexpressed in metastatic melanomas
in comparison with dysplastic nevi and primary melanoma.
Thus, we speculate that increased expression of PAR-1 in
metastatic melanomas is likely involved in tumor progression
and is associated with metastatic potential. PAR-1 has been
proposed to be involved in the invasive and metastatic
processes of several cancers including breast, colon, lung,
pancreas, prostate, and melanoma (Nierodzik et al., 1992,
1998; Fischer et al., 1995; Even-Ram et al., 1998, 2001; Zain
et al., 2000). Supportive evidence includes the observation
that PAR-1 has oncogenic properties in NIH-3T3 cells
(Whitehead et al., 1995) via activation of Rho-mediated
pathways (Martin et al., 2001). Boire et al. (2005) reported
that a matrix metalloproteinase (MMP), MMP-1, targets
PAR-1 on breast cancer cells to confer a promigratory and
proinvasive phenotype. First, they showed that MCF-7, a
breast cancer cell line known to be deficient in PAR-1 and
non-invasive in vitro and non-tumorigenic in nude mice
(Even-Ram et al., 1998), can be converted into an invasive,
tumorigenic cell line by transfection with a functional PAR-1
gene, but not by transfection with the non-activating mutant
(Boire et al., 2005). Secondly, they demonstrated that small
interfering RNA knockdown of PAR-1 in MDA-MB-231 cells
rendered them non-invasive and unable to migrate (Boire
et al., 2005). Others have demonstrated that ectopic
expression of PAR-1 in mammary gland epithelia produces
an oncogenic phenotype of enhanced ductal complexity in
mice (Yin et al., 2003a). We previously demonstrated that
PAR-1 expression in established human melanoma cell lines
is directly correlated with their metastatic potential (Tellez
et al., 2003).
Beyond its roles in normal vascular regulation and tissue
remodeling, PAR-1 may facilitate tumor invasion, angio-
genesis, and metastasis by modulating the expression of cell
adhesion molecules, matrix-degrading proteases and the
secretion of angiogenic factors. Thrombin activates PAR-1
and promotes tumor cell adhesion to endothelial cells,
Table 1. Summary statistics for AP-2 expression
Diagnosis group N Mean SD Min. Median Max. P-value DN versus P-value PM versus
DN 21 23.33 16.40 3.25 18.75 56.70 — —
PM 20 21.11 14.12 3.00 18.35 58.20 0.7461 —
MM 23 8.99 11.36 0.10 4.30 49.35 0.0013 0.0023
AP-2, activator protein-2; DN, dysplastic nevi; MM, melanoma metastasis; PM, primary melanoma; SD, standard deviation.
Table 2. Summary statistics for PAR-1
Diagnosis group N Mean SD Min. Median Max. P-value DN versus P-value PM versus
DN 21 57.93 21.44 18.30 63.45 87.05 — —
PM 20 60.08 21.25 14.40 60.78 92.45 0.7856 —
MM 23 74.65 28.06 1.00 87.90 98.15 0.0072 0.0138
DN, dysplastic nevi; MM, melanoma metastasis; PAR-1, protease-activated receptor-1; PM, primary melanoma; SD, standard deviation.
Table 3. Spearman correlations between AP-2 and
PAR-1 expression
Diagnosis group R P-value
DN 0.94 o0.0001
PM 0.68 0.0010
MM 0.91 o0.0001
AP-2, activator protein-2; DN, dysplastic nevi; MM, melanoma metas-
tasis; PAR-1, protease-activated receptor-1; PM, primary melanoma.
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subendothelial matrix, fibronectin, and von Willebrand factor
under static conditions, and platelet-dependent melanoma
cell adhesion to endothelial cells under flow conditions, by
enhanced expression of a-IIbb-3 and other cell surface
molecules, such as P-selectin (Klepfish et al., 1993; Wojtu-
kiewicz et al., 1993, 1995; Nierodzik et al., 1995; Dardik
et al., 1998). Activation of PAR-1 leads to synthesis and
secretion of functional vascular endothelial growth factor
proteins, which are highly effective in eliciting tumor
angiogenesis in stable PAR-1-transfected melanoma cells
(Yin et al., 2003b). Many of the gene products induced by
PAR-1 activation are precisely those required for tumor
angiogenesis and invasion, including IL-8 (Ueno et al., 1996),
basic fibroblast growth factor (Cucina et al., 1999), platelet-
derived growth factor (Shimizu et al., 2000), and MMP-2
(Zucker et al., 1995). Although no clinical studies have been
published to date using PAR-1 antagonists, it has been shown
that antisense cDNA directed against PAR-1 inhibits breast
carcinoma invasion in a mouse model system (Even-Ram
et al., 1998), suggesting a possible therapeutic use for PAR-1
blockade in cancer.
In summary, we have shown that AP-2 is highly expressed
in dysplastic nevi and primary melanoma and we demon-
strate that there is a significant reduction of AP-2 expression
in metastatic melanomas. We hypothesize that reduced
expression of AP-2 in melanomas may be involved in tumor
progression and likely plays a role in determining the
metastatic potential of these tumors. Furthermore, we have
shown that high expression of PAR-1 is significantly
correlated with melanoma progression, suggesting that PAR-1
may be involved in survival, growth, and invasive properties
of metastatic melanoma cells. A major finding in our study is
that the upregulation of PAR-1 expression in malignant
melanomas significantly correlated with diminished AP-2
expression. Interestingly, we observed a subpopulation of
melanocytic cells that are positive for AP-2 and PAR-1. We
hypothesized that this is likely due to subcellular changes in
expression of AP-2. Our previous findings demonstrated that
cytoplasmic expression of AP-2 significantly increased with
melanoma progression (Berger et al., 2005). Furthermore, we
have previously identified PAR-1 as an AP-2 target gene that
plays an active role in tumor progression (Tellez et al., 2003).
In agreement with our previous findings, these results also
suggest that radial growth phase to vertical growth phase
transformation is likely associated with the loss of AP-2
expression and induction of PAR-1 gene expression (Tellez
and Bar-Eli 2003; Tellez et al., 2003), and supports our
hypothesis that loss of AP-2 function is a crucial event in the
progression of human melanomas. Furthermore, loss of AP-2
expression results in deregulation of target genes involved in
tumor progression and metastasis of melanoma, such as
MUC18 (Jean et al., 1998), c-KIT (Huang et al., 1998),
MMP-2 (Gershenwald et al., 2001), E-cadherin (Batsche
et al., 1998), p21WAF-1 (Zeng et al., 1997b), VEGF (vascular
endothelial growth factor) (Gille et al., 1997), TGF-a
(transforming growth factor-a) (Wang et al., 1997), and
HGF (hepatocyte growth factor) (Jiang et al., 2000). This
study also demonstrates the power of an automated analysis
to detect changes in expression of AP-2 and PAR-1 in
melanocytic cells, which may serve as sensitive markers to
monitor the progression of melanoma.
MATERIALS AND METHODS
Patients and case selection
The pathology database at The University of Texas M.D. Anderson
Cancer Center was retrospectively reviewed, and we randomly
selected cases of benign and malignant melanocytic lesions
diagnosed in our institution between January 2000 and December
2001. There were identified 64 patients with various melanocytic
lesions including, 21 dysplastic nevi, 20 primary melanomas (four
cases of radial growth phase and 16 cases of vertical growth phase
including, eight superficial spreading, two nodular, four acral
lentiginous, and six lentigo maligna), and 23 melanoma metastases
(10 subcutaneous, six lymph node, seven visceral). The Institutional
Review Board approved the use of the human specimens for this
investigation.
Construction of tissue microarray
Tissue microarray construction was previously described by Shen
et al. (2003) and was designed to assess markers along the
progression of normal melanocytic lesions to metastatic melanoma
and was not designed to be a prognostic array. In brief, tissue
sections from formalin-fixed paraffin donor blocks were stained with
hematoxylin and eosin and reviewed by a pathologist to define the
areas to be selected for analysis. To preserve the original tissue
block, either 0.6 mm (biopsy specimens) or 1.0 mm (excision
specimens) cylindrical cores of tissue were punched out from the
donor blocks. All of the melanocytic lesions were sampled in
duplicate, and two control cases (one benign nevus and one
malignant melanoma) were included in all three microarray blocks
to serve as baseline controls. Selected tissue cores were inserted in a
standard 4.5 2 1 cm recipient block using a Tissue Microarrayer
(Beecher Instruments, Silver Spring, MD) with an edge-to-edge
distance of 0.1 or 0.15 mm. The tissue microarrays were cut to 5 mm
sections and placed on glass slides using an adhesive tape transfer
system (Instumedics Inc., Hackensack, NJ) with UV cross-linking.
A serial section from each tissue array was stained with hematoxylin
and eosin to verify the presences of the lesion and excluded necrotic
tissue from the quantitative LSC analysis.
Immunofluorescent detection of MART-1, AP-2, and PAR-1 for
laser scanning cytometric analysis
Tissue microarray sections were deparaffinized in xylene, rehydrated
in alcohol, and transferred to phosphate-buffered saline (PBS).
Antigen retrieval was performed by steaming using antigen retrieval
solution (Dako, Carpinteria, CA) for 45 minutes followed by cooling
at room temperature for 20 minutes. Next, tissues were washed three
times for 3 minutes with PBS and incubated with protein block (5%
normal horse serum in PBS) for 15 minutes at room temperature.
Protein block was drained, and tissues were incubated with a 1:50
dilution of commercially available monoclonal anti-AP-2 (Serotec,
Raleigh, NC) specific for human AP-2a (can also recognize AP-2b
isoform) in protein block overnight at 41C. Tissues were washed with
PBS three times for 3 minutes and then incubated in the dark with a
1:400 dilution of secondary anti-mouse antibody conjugated to
Alexa 488 for 2 hours at room temperature. All samples were
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henceforth protected from exposure to light. Tissues were washed
with PBS containing 0.1% Brij for 3 minutes two times and once with
PBS for 3 minutes followed by incubation with protein block (5%
normal horse serum in PBS) for 15 minutes at room temperature.
Next, tissues were incubated with a 1:200 dilution of mouse
monoclonal anti-MART-1 (Dako) in protein block overnight at 41C
and then washed with PBS three times for 3 minutes and incubated
with a 1:400 dilution of secondary anti-mouse antibody conjugated
to phycoerythrin. Tissues were washed with PBS containing 0.1%
Brij for 3 minutes two times and once with PBS for 3 minutes and
incubated with protein block for 15 minutes at room temperature.
The tissues were then incubated with a 1:20 dilution of monoclonal
anti-PAR-1 (WEDE15; Immunotech-Coulter, Miami, FL) overnight at
41C. The tissues were washed with PBS containing 0.1% Brij for
3 minutes two times, and once with PBS for 3 minutes and then
incubated with a 1:800 dilution of secondary anti-mouse antibody
conjugated to cyanine 5.
Laser scanning cytometric analysis
LSC (CompuCyte Corporation, Cambridge, MA) combines flow
cytometry, image analysis, and automated fluorescence microscopy
to enable fluorescence-based quantitative measurements at the
single-cell level. The LSC consists of an Olympus BX50 fluorescent
microscope and a computer-controlled optics unit coupled to an
argon, HeNe, and violet laser. Multiple lasers are used to
simultaneously excite different fluorochromes in cellular specimens
that emit discrete wavelengths detected by a set of photomultiplier
tubes. Together, these features permit the ability to generate high-
content stoichiometric data on heterogeneous populations of large
numbers of cells. Thus, the LSC was used very much like a FACS to
obtain three-color immunofluorescence intensity information from
the tissue microarrays. We selected each fluorochrome based on the
experimental end point of the study and compatibility with the LSC.
Importantly, each probe was independently tested to ensure non-
overlapping emission between filters. Using the Wincyte software,
argon and HeNe lasers were selected with the appropriate filters to
detect long-red (MART-1), red (PAR-1), and green (AP-2) fluores-
cence. Once the scan region was selected using the epifluorescent
microscope, slides were scanned using a  200 objective and
detector gain voltages were set so that a maximum of 50% saturation
was achieved for the brightest maximum pixel event scanned for
each fluorochrome. The minimum area threshold was set to optimize
contouring of single-cell nuclei of MART-1-positive cells. To
determine the percentage of AP-2-positive and PAR-1-positive cells,
a scattergram was created to define four quadrants that determined
which cells were positive. Each gate of the scattergram was set based
on the fluorescent properties of the negative control sample stained
with each fluorescent probe. Once each slide was scanned, the data
file was replayed to determine the percentages of each cell
population, for example, MART-1-positive/AP-2-positive/PAR-1-
positive cells for each tissue core.
Statistical analysis
Summary statistics including the mean, SD, median, and range were
computed by diagnosis group for the number of AP-2- and PAR-1-
positive cells. Initially, Shapiro–Wilk tests were performed to
evaluate the normality of the data. AP-2 and PAR-1 cell numbers
were compared between all three groups using a Kruskal–Wallis test.
In addition, Wilcoxon rank-sum tests were performed to compare the
number of AP-2- and PAR-1-positive cells between two pairs of
diagnosis groups: dysplastic nevi versus primary melanoma,
dysplastic nevi versus metastatic melanoma, and primary melanoma
versus metastatic melanoma. As the overall comparison of the three
groups was statistically significant, the significance level for the
multiple comparisons was not adjusted. Furthermore, Spearman rank
correlation coefficients between the percentages of AP-2- and
PAR-1-positive cells were computed separately within each group.
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